HER2 status and benefit from adjuvant trastuzumab in breast cancer

N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism
  • Chemotherapy, Adjuvant
  • Female
  • Gene Amplification
  • Genes, erbB-2
  • Humans
  • RNA, Messenger / metabolism
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / metabolism*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • RNA, Messenger
  • Receptor, ErbB-2
  • Trastuzumab